"Uterus Transplantation – A Primer for Transplant Professionals"
Co-sponsored by the Transplant Pharmacy Community of Practice (TxPharm COP), Vascularized Composite Allotransplantation Advisory Council (VCA AC), and the Women's Health Community of Practice (WHCOP)

Presenters:
- Teena Sam, PharmD (Baylor University Medical Center)
- Paige Porrett, MD, PhD (University of Alabama at Birmingham)

Moderator:
- Silvi Shah, MD, MS (University of Cincinnati)

Target Audience: Transplant professionals (trainees and seasoned practitioners)

Speakers:

• Holly Mansell, PharmD, BSP • Associate Professor of Pharmacy, University of Saskatchewan, Saskatoon, SK
• Tiffany Kaiser, PharmD, MS, FCCP, BCPS • Associate Professor of Medicine, University of Cincinnati, Cincinnati, OH

Moderator:

• Patricia West-Thielke, PharmD, BCPS, FAST • Director of Clinical Research, University of Illinois at Chicago, Chicago, IL

Tuesday, September 8, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted jointly by the TCC & TxPharm Communities of Practice

"Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients."
(Am J Transplant. 2020 Jun 18. doi: 10.1111/ajt.16155. Online ahead of print.)

In this article:
[The authors] previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. [The authors] sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied... [Results] indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk.

Speaker:
Richard Daly, MD • Mayo Clinic College of Medicine, Rochester, MN

Moderator:
Douglas Jennings, PharmD, FACC, FAHA, FHFSA • Long Island University, Brooklyn, NY

AST/AJT Journal Clubs are free for both members and non-members. Pre-registration is required.

Tuesday, December 3rd, 2019, from 2:00 PM ET to 3:00 PM ET • Hosted by theTransplant Pharmacy Community of Practice (TxPharm COP)

""Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study."
(Am J Transplant. 2019 Sep 11. doi: 10.1111/ajt.15591. [Epub ahead of print])

In this article:
This study assessed the efficacy and safety of the anti-CD40 monoclonal antibody bleselumab (ASKP1240) in de novo kidney transplant recipients over 36 months posttransplant.... For the primary endpoint (incidence of biopsy-proven acute rejection [BPAR] at 6 months), bleselumab + IR-TAC was noninferior to SoC, and bleselumab + MMF did not demonstrate noninferiority to SoC. BPAR incidence slightly increased through month 36 in all groups, with bleselumab + IR-TAC continuing to demonstrate noninferiority to SoC. Bleselumab had a favorable benefit-risk ratio. Most treatment-emergent adverse events were as expected for kidney transplant recipients (see also ClinicalTrials.gov NCT01780844).

Speaker:
Bharath Ravichandran, PharmD • University of Maryland Medical Center, Baltimore, MD

Moderator:
Stephen Jensik, MD • Rush University Medical Center, Chicago, IL

AST/AJT Journal Clubs are free to both members and non-members. Pre-register today to support this TxPharm COP session, and please feel free to share the registration link with your colleagues!